The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Obesity is an epidemiological issue that negatively affects public health and has led to a high global burden on the healthcare system. Several approaches to control and overcome the obesity crisis have been established. However, Nobel discoverers found that glucagon-like peptide-1 analogues (GLP-1 analogues) positively regulate appetite and food intake, eventually leading to weight loss. Objective: The present systematic review aims to summarize the currently available evidence of the impact of GLP-1 analogues on appetite, gastric emptying, taste sensitivity, and food preferences among adults with obesity without other chronic diseases. Methods: A systematic literature search was conducted from October 2021 to December 2021 from three electronic databases (PubMed, Scopus, and ScienceDirect), including only randomized clinical trials (RCTs). Studies were based on the use of GLP-1 analogues, of any dosage and duration among adults with obesity without other medical diseases; studies measured appetite, gastric emptying, food preferences, and taste as a primary or secondary outcome. The risk of publication bias in each study was assessed independently using the updated Cochrane risk-of-bias tool (RoB2). Results: Twelve studies met the inclusion criteria with a total sample size of 445 participants. All the included studies measured at least one or more of the primary outcomes. The promising effect was evidenced by most studies showing appetite suppression, delayed gastric emptying, and changes in taste and food preferences. Conclusion: GLP-1 analogues are effective obesity management therapy that could decrease food intake and eventually reduce weight by suppressing appetite, reducing hunger, decreasing gastric emptying, and altering food preferences and taste. However, high-quality, long-term, large sample size studies are crucial to examine the efficacy and effective dose of GLP-1 analogues intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This group of drugs slows the rate of post‐prandial gastric emptying [2, 3, 4]”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“GLP-1 analogues induce weight loss through multiple mechanistic properties, including insulin stimulation, inhibition of glucagon secretion, delaying gastric emptying, enhancing satiety, reducing hunger, reducing energy intake, and regulating appetite and food reward.(11,13,14) A multiplex brain-gut interaction orches…”
BackgroundAppetite control: methodological aspects of the evaluation of foods
Blundell, J., De Graaf, C., Hulshof, T., Jebb, S., Livingstone, B., Lluch, A., Mela, D., Salah, S., Schuring, E., Van Der Knaap, H., et al. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00714.x · Cited by 1,007
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Research works printed but not linked: 4
- Van Bloemendaal, 2014, Diabetes, 2014, 1
- Kadouh, 2020, Cad Saude Publica, 12, 1
- Kamioka, 2019, Japanese Pharmacol Ther, 47, 1177
- Hill, 1995, Int J Obes Relat Metab Disord J Int Assoc Study Obes, 1995, 361
Cited by
Items 101–132 of 132
The Effects of GLP-1 Agonists on Cardiac Structure and Function: A Systematic Review
Sarjian, S., Kazaryan, J. A., & Melkonian, A. (2025) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.898
Rêgo, A. N. C., de Castro, D. S., & dos Reis, A. V. (2025) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n6-342
Análogos del receptor GLP1 y consideraciones en el manejo perioperatorio: una revisión narrativa
Lima, A. V., & Lopo, M. V. (2025) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2025.501985
do Nascimento, T. S., Pereira, R. O. L., Maia, E. R., Ohnuma, T., da Costa, M. G., Slawka, E., Galhardo, C., & Krishnamoorthy, V. (2024) · Figshare · doi:10.6084/m9.figshare.26752558
do Nascimento, T. S., Pereira, R. O. L., Maia, E. R., Ohnuma, T., da Costa, M. G., Slawka, E., Galhardo, C., & Krishnamoorthy, V. (2024) · Figshare · doi:10.6084/m9.figshare.26752561
Exploring Neurocognitive Factors Underlying Autism and Hyperphagia in Prader-Willi Syndrome
Feighan, S.-M. (2024) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
What Are the Impacts of GLP ‐1 Drugs in Patients Needing Head/Neck Surgery?
Gelboin‐Burkhart, C., Gallagher, L. W., Ebert, B. E., & Khariwala, S. S. (2025) · The Laryngoscope · doi:10.1002/lary.70341
Prior preferences interfere with the associative learning of food values
Rich, A., Kapadia, S., Henry, R., Dan, O., & Levy, I. (2026) · Communications Psychology · doi:10.1038/s44271-026-00533-5
Qin, W., Song, T., Lai, Z., Li, D., Wang, L., & Huang, R. (2026) · eLife · doi:10.7554/elife.108551.2
Exosome-Mimicking Nanoparticles: Next-Generation Therapeutics for Obesity-Induced Type 2 Diabetes
Edgar, M. (2026) · International Academic Association Journal of Scientific Research. · doi:10.59298/iaajsr/2026/131135140
Abioke, U. B., Baiden, I., Okeoma, O. I., Partey-Newman, V., Adewale, T. O., Onyekezini, S. O., & Okwuowulu, I. L. (2026) · Epidemiology and Health Data Insights · doi:10.63946/ehdi/18334
Liang, Y.-K., Zhang, J.-H., Liang, S., Wu, S.-W., & Feng, X.-Y. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i4.115698
Odoeke, M. C., Okwu, S., Bassey, E., Oladimeji, A. O., Aboflah, T.-W. D., Adelola, S., Ewejobi, M., Ugwuchukwu, N. H., Alrowaili, D. G., & Okobi, O. E. (2026) · Cureus · doi:10.7759/cureus.108646
Bcharah, G., Wininger, A. E., Elsabbagh, Z., Braithwaite, C. L., Schuyver, P. R. V., Spangehl, M. J., Clarke, H. D., & Bingham, J. S. (2026) · Arthroplasty Today · doi:10.1016/j.artd.2026.102033
Kim, G., Fang, W., Chung, J., Dunn, E., Lin, R., Mo, K., & Lee, D. (2026) · Journal of the American Osteopathic Academy of Orthopedics · doi:10.70709/pmiw7lkpkareon
Diabetes and Weight Management
Perry, M. L. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch13 · Cited by 1
Čermáková, E. (2026) · Medicína pro praxi · doi:10.36290/med.2026.025
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Heshmati, J., Mahmoodianfard, S., Raizman, E., Abraham, A., & Mir, H. R. (2026) · Tobacco Induced Diseases · doi:10.18332/tid/219815
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Rasul, M., Hassan, A., Rehman, U. U., Sarmad, M., Farooq, A. S., Khalil, H., Jahangir, M. A., Abideen, Z. U., Bashir, M. K., Cheema, U., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261473919
Hassan, A., Farooq, Q. U. A., Parwesh, F., Rasul, M., Masood, A., Aftab, H., Riaz, H., Mahmood, A., Malik, M. A., Rehman, A. U., et al. (2026) · F1000Research · doi:10.12688/f1000research.186847.1
How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity
Ayyad, M., & Kim, E. (2026) · Obesity · doi:10.1002/oby.70285
Peixoto, M. J. D., da Silva, V. W. C., Carvalho, G. S., Gomes, B. M., de Almeida, K. T. L., Collega, R., Montanhini, L. M., Guijo, V. D. S., Marques, L. M., Marques, M. C. M., et al. (2026) · Derecho y cambio social. · doi:10.54899/dcs.v23i96.7001
Ozempic: Use, Misuse, and Implications for the Treatment of Obesity.
Condrat, A. (2026) · Health Science Inquiry · doi:10.29173/24mnwh21
GLP-1-Based Therapies in Eating Disorder Recovery
Cunanan, A. L. P., Zito, K., Cho, Y., Oliver, R., Onyemailu, V., & Munn‐Chernoff, M. A. (2026) · Pharmaceuticals · doi:10.20944/preprints202609.2026.v1
Renier, T. J., Carlson, D. D., Gilbert‐Diamond, D., & Emond, J. A. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70146
Cisneros, J. Z., Camilleri, M., & Grover, M. (2026) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v56i3.690
ANÁLISE DOS ANÁLOGOS DE GLP-1 NA MODULAÇÃO DO COMPORTAMENTO ALIMENTAR E NA RELAÇÃO COM A COMIDA
Xavier, B. L. S., de Sousa, E. V. M., Freitas, F. M. N. D. O., & dos Reis, D. S. (2026) · Periódicos Brasil Pesquisa Científica · doi:10.36557/2674-9432.2026v5n8p691-705
Dakin, C. A., Beaumont, J. D., & O’Hara, B. (2026) · Obesity Reviews · doi:10.1111/obr.70245
Floyd, K., Sharma, M., & Du, X. (2026) · Food Research International · doi:10.1016/j.foodres.2026.121169
Metadata
- Authors
- Aldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M.
- Affiliations
- King Saud University (SA)
- Corresponding author
- Aldawsari, Malikah
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2023-03
- Volume
- Volume 16
- Pages
- 575-595
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC9987242
- OpenAlex
- W4322773858
- Semantic Scholar
- bfb01b3839e12cdd8d7b7f8b07656fbd58ec6987
- Cited by
- 115
- References
- 44
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 34 · 2023: 8
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- King Saud University
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, obesity, appetite suppression, gastric emptying, food preferences, taste sensitivity, weight loss, dietary intake
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


